ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ) has provided an update.
ImmuneOnco Biopharmaceuticals has received approval from the Hong Kong Stock Exchange for the listing and trading of 14,114,006 converted H shares, as part of its participation in the H share full circulation program. This approval marks a significant step in the company’s efforts to enhance its market presence and liquidity, with the converted shares representing approximately 3.56% of the total issued H shares.
More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biopharmaceutical company based in China, focusing on the development and commercialization of innovative cancer immunotherapy products. The company operates in the healthcare sector, aiming to provide advanced treatment options for cancer patients.
YTD Price Performance: 24.03%
Average Trading Volume: 6,410,493
Technical Sentiment Signal: Hold
Current Market Cap: HK$2.22B
Find detailed analytics on 1541 stock on TipRanks’ Stock Analysis page.